Infectious Diseases

Anti-phage аntibody response in phage therapy against healthcare-associated infections (HAIs)

Authors / Institutions

S.S.Bochkareva / G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russian Federation

A.V.Aleshkin / G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russian Federation

O.N.Ershova / N.N.Burdenko Neurosurgery Research Institute, Moscow, Russian Federation

L.I.Novikova / G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russian Federation

A.V.Karaulov / I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

I.A.Kiseleva / G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russian Federation

E.R.Zul'karneev / G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russian Federation

E.O.Rubalskiy / G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russian Federation

M.V.Zeigarnik / N.I.Pirogov Russian National Research Medical University, Moscow, Russian Federation / «Nutrition and Health» Medical Center, Moscow, Russian Federation
The objective. To evaluate anti-phage аntibody response in phage therapy against HAIs.

Patients and methods. Forty-two patients on prolonged mechanical ventilation in a neurological ICU were administered bacteriophage cocktail per os, including six patients repeatedly – from 3 to 5 courses. Anti-phage immunity was evaluated by ELISA before and after the treatment.

Results. Initially, from 87.5% of the patients’ samples A. baumannii, K. pneumoniae, P. aeruginosa were isolated. In the first courses of phage therapy, effective sanitation was proved in 54–62.5% of cases. Pharmacokinetic research assumed a systemic action of enteral forms of bacteriophages. Repeated courses of phage therapy with the same strains did not lead to a substantial eradication of pathogens. Anti-phage immunity after a single application of bacteriophage cocktail with a certain composition of strains was detected with ELISA by the presence of titer of specific IgG antibodies in the range of 1/16-1/4096 (no antibodies were present in patients who did not take the cocktail).

Conclusion. The effectiveness of a bacteriophage may be reduced if a patient is given a repeated treatment due to the formation of anti-phage antibodies. In order to retain performance of phage therapy, a change in the composition of strains in the phage cocktail is necessary.

Key words: bacteriophages, HAIs, antibiotic resistance, humoral immune response, anti-phage antibodies.

For citation: Bochkareva S.S., Aleshkin A.V., Ershova O.N., Novikova L.I., Karaulov A.V., Kiseleva I.A., Zul’karneev E.R., Rubal’skiy E.O., Zeigarnik M.V. Anti-phage аntibody response in phage therapy against healthcare-associated infections (HAIs). Infekc. bolezni (Infectious diseases). 2017; 15(1): 35–40.
DOI: 10.20953/1729-9225-2017-1-35-40

Яндекс.Метрика